Data on the evaluation of FGF2 gene expression in Colorectal Cancer

Caiado, Helena; Conceição, Natércia; Tiago, Daniel M.; Marreiros, Ana; Vicente, S.; Enriquez, Jose Luis; Vaz, Ana; Antunes, Artur; Guerreiro, Horácio; Caldeira, Paulo; Cancela, M. Leonor

doi:10.1016/j.dib.2020.105765

Cited by 12 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the upregulated MMPs, the promoters of MMP1, MMP3, MMP7, MMP9, MMP10, MMP12, and MMP13 have a TATA box and AP-1 binding sites [7], consistent with observations that some MMPs are co-regulated in their expression. Since several cytokines or growth factors, well recognized as prognostic factors for CRC, including platelet-derived growth factor (PDGF) [8], tumor necrosis factor-α (TNF-α) [9], interleukins (ILs) [10], epidermal growth factor (EGF) [11], vascular endothelial growth factor (VEGF) [12] basic fibroblast growth factor (bFGF) [13,14] and the TGFβ [15] interact with TATA box and AP-1 elements, we surmise that they can participate in deregulation of MMP expression in CRC. Surprisingly, among the upregulated MMPs, MMP-2 did not show the inclusion criteria to consider it as upregulated in CRC, infact only in the UALCAN database, MMP2 was significantly upregulated in CRC compared to normal adjacent tissues.…”

Section: Discussionmentioning

confidence: 99%

“…MMPs are deregulated in almost every type of cancer and their expression is linked to a variety of aspects of cancer progression, including proliferation, invasion, EMT, metastasis, and angiogenesis [11]. MMPs are often associated with a poor prognosis in several cancer types [12][13][14]. In colon cancer, the expression of MMPs increases along with tumor progression and some MMPs correlate with tumor invasion, metastasis, or poorer outcomes [15][16][17][18], although some MMPs have been shown to perform tumor-protective effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Integrated Multi-Omics Investigations of Metalloproteinases in Colon Cancer: Focus on MMP2 and MMP9

Buttacavoli

Cara

Roz

et al. 2021

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) develops by genetic and epigenetic alterations. However, the molecular mechanisms underlying metastatic dissemination remain unclear and could benefit from multi-omics investigations of specific protein families. Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in ECM remodeling and the processing of bioactive molecules. Increased MMP expression promotes the hallmarks of tumor progression, including angiogenesis, invasion, and metastasis, and is correlated with a shortened survival. Nevertheless, the collective role and the possible coordination of MMP members in CRC are poorly investigated. Here, we performed a multi-omics analysis of MMP expression in CRC using data mining and experimental investigations. Several databases were used to deeply mine different expressions between tumor and normal tissues, the genetic and epigenetic alterations, the prognostic value as well as the interrelationships with tumor immune-infiltrating cells (TIICs). A special focus was placed on to MMP2 and MMP9: their expression was correlated with immune markers and the interaction network of co-expressed genes disclosed their implication in epithelial to mesenchymal transition (EMT) and immune response. Finally, the activity levels of MMP2 and MMP9 in a cohort of colon cancer samples, including tissues and the corresponding sera, was also investigated by zymography. Our findings suggested that MMPs could have a high potency, as they are targeted in colon cancer, and might serve as novel biomarkers, especially for their involvement in the immune response. However, further studies are needed to explore the detailed biological functions and molecular mechanisms of MMPs in CRC, also in consideration of their expression and different regulation in several tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Integrated Multi-Omics Investigations of Metalloproteinases in Colon Cancer: Focus on MMP2 and MMP9

Buttacavoli

Cara

Roz

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…FGF2 is a member of fibroblast growth factor family, which has been reported to participate in several tumor-related pathways, such as cell growth, differentiation, and angiogenesis ( Akl et al, 2016 ). Studies have shown that FGF2 is significantly overexpressed in CRC tissues compared to normal tissues, and CRC patients with high FGF2 expression showed poorer prognosis than those with low expression ( Caiado et al, 2020 ). NRG1 gene is an emerging, potentially actionable oncogenic driver that can promotes pathologic signaling such as MAPK and ERBB pathways ( Jonna et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer

Han

Wang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Anti-cancer immunotherapeutic approaches have gained significant efficacy in multiple cancer types. However, not all patients with colorectal cancer (CRC) could benefit from immunotherapy due to tumor heterogeneity. The purpose of this study was to construct an immune-related signature for predicting the immune characteristics and prognosis of CRC.Methods: RNA-sequencing data and corresponding clinical information of patients with CRC were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), and immune-related genes (IRGs) were downloaded from the Immunology Database and Analysis Portal (ImmPort). Then, we utilized univariate, lasso regression, and multivariate cox regression to identify prognostic IRGs and develop the immune-related signature. Subsequently, a nomogram was established based on the signature and other prognostic factors, and its predictive capacity was assessed by receiver operating characteristic (ROC) and decision curve analysis (DCA). Finally, associations between the signature and the immune characteristics of CRC were assessed.Results: In total, 472 samples downloaded from TCGA were divided into the training cohort (236 samples) and internal validation cohort (236 samples), and the GEO cohort was downloaded as an external validation cohort (122 samples). A total of 476 differently expressed IRGs were identified, 17 of which were significantly correlated to the prognosis of CRC patients. Finally, 10 IRGs were filtered out to construct the risk score signature, and patients were divided into low- and high-risk groups according to the median of risk scores in the training cohort. The high-risk score was significantly correlated with unfavorable survival outcomes and aggressive clinicopathological characteristics in CRC patients, and the results were further confirmed in the internal validation cohort, entire TCGA cohort, and external validation cohort. Immune infiltration analysis revealed that patients in the low-risk group infiltrated with high tumor-infiltrating immune cell (TIIC) abundances compared to the high-risk group. Moreover, we also found that the immune checkpoint biomarkers were significantly overexpressed in the low-risk group.Conclusion: The prognostic signature established by IRGs showed a promising clinical value for predicting the prognosis and immune characteristics of human CRC, which contribute to individualized treatment decisions.

show abstract

“…Several studies have shown that CXCL13 is involved to mediate 5-Fu resistance mechanism and considered to be a biomarker for predicting the prognosis of colorectal cancer, which is consistent with our ndings (47,48). FGF2, a member of the broblast growth factor (FGF) family whose signaling network has been implicated in several pathways, such as normal cell growth, differentiation, angiogenesis and tumor development, signi cantly promotes tumor cell differentiation and proliferation (49,50). FGF7, also called keratinocyte growth factor (KGF), is involved in inducing vascular endothelial growth factor (VEGF)-A expression, which plays important roles in the angiogenesis and metastasis of various cancer cells including colorectal cancer (51,52).…”

Section: Discussionmentioning

confidence: 99%

Development and validation of immune-related genomics nomogram for prognostic prediction in left- and right-side colorectal cancer

Niu

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Previous studies have reported that the tumor heterogeneity and immune molecular mechanisms of proximal and distal colorectal cancer (CRC) are divergent. Therefore, our study aims to analyze the difference between left-sided CRC (LCC) and right-sided CRC (RCC), and respectively develop the nomograms based on prognostic immune-related genes for LCC and RCC. Methods: We enrolled 443 colon cancer patients (220 LCC patients and 223 patients) from The Cancer Genome Atlas (TCGA) datasets. Firstly, the differential expressed immune-related genes (DE-IRGs), overall survival (OS), and biological functions between LCC and RCC groups were identified. Then, we analyzed the differences between the two groups in the immune microenvironment, immune checkpoint, and tumor mutation burden (TMB). Next, the LCC and RCC data from TCGA dataset are randomly divided into training and internal validation sets at a 7:3 ratio respectively. Additionally, 566 colon cancer patients (342 LCC patients and 224 RCC patients) in the GSE39582 dataset were downloaded from the Gene Expression Omnibus (GEO) database as the external validation set. Then, survival and Lasso Cox regression analyses were applied to identify hub immune-related genes and respectively establish two prognostic gene signatures of LCC and RCC groups. The prognostic signatures were validated by the 10-fold cross-validation, internal validation set, and external validation set. Further, combined with clinical features, we constructed two clinical predictive nomograms and validated them. Results: RCC patients have lower survival than LCC. RCC patients have higher proportions of T cells CD8, T cells follicular helper, and lower macrophages M0, T cells CD4 naive. RCC patients have higher ESTIMATE and immune scores and lower tumor purity. The immune checkpoint expression levels and TMB values are higher in RCC patients than in LCC. We respectively selected 10 immune-related genes for LCC and 7 genes for RCC groups to develop and validate the prognostic model and calculate a risk score for each patient. The AUC values of the risk score for OS in LCC were 0.735 in the training set, 0.711 in the internal validation set, and 0.744 in the external validation set, and in RCC were 0.704 in the training set, 0.738 in the internal validation set, and 0.705 in the external validation set. The AUC values of the 10-fold cross-validation range from 0.564 to 0.808 in LCC and from 0.589 to 0.792 in RCC. The nomogram of LCC of RCC includes risk based on prognostic genes, age, pathological T, N, M, stage, and gender. the AUC values of the LCC nomogram were 0.722 in the training set, 0.696 in the internal validation set, and 0.739 in the external validation set, and of the RCC nomogram were 0.774 in the training set, 0.744 in the internal validation set, and 0.737 in the external validation set. We also found that were significantly different between high- and low-risk patients in the immune score, ESTIMATE score, tumor purity, immune checkpoint expression levels, and TMB values. Conclusions: We found significant differences in the multidimensional insight between LCC and RCC patients in clinical features, DE-IRGs, TMB, immune checkpoint expression levels, and immune microenvironment landscape. Our study respectively established two prognostic nomograms based on DE-IRGs in combination with clinical features to provide a basis for personalized and precise treatment of LCC and RCC patients.

show abstract

Data on the evaluation of FGF2 gene expression in Colorectal Cancer

Cited by 12 publications

References 9 publications

Integrated Multi-Omics Investigations of Metalloproteinases in Colon Cancer: Focus on MMP2 and MMP9

Integrated Multi-Omics Investigations of Metalloproteinases in Colon Cancer: Focus on MMP2 and MMP9

Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer

Development and validation of immune-related genomics nomogram for prognostic prediction in left- and right-side colorectal cancer

Contact Info

Product

Resources

About